History

_x000D_ Abbott India Ltd. is one of the leading multinational pharmaceutical companies in India. It operates with an owned manufacturing facility in Goa and various independent contract/third-party manufacturers based across the country. Abbott India Ltd was originally incorporated on August 22, 1944, as Boots Pure Drug Company (India) Ltd. On July 1, 2002, they got their present name, Abbott India Ltd. _x000D_ _x000D_ In the year 2004, the company started the production of capsules and nutritional products. During the financial year ended March 31, 2016, Abbott India launched 17 new products in various therapy segments, which together contributed 1.9% of the net sales of the company. In the same year, the company entered into a licensing arrangement with Bharat Biotech India Limited to market vaccines in the immunology segment. During FY 2019, the company executed 25 new studies and published 45 articles in major indexed journals, with 6 international presentations._x000D_ _x000D_ During the year 2022, the company continued portfolio expansion and launched 10 new differentiated products in the market to meet increasing healthcare needs. It increased presence in high-growth therapy areas such as adult vaccination and new sub-therapies like menopause. _x000D_

Business Segments

_x000D_ Abbott India provides products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc. Its global products include Brufen, Prothiaden, Thyronorm and Leptos._x000D_ _x000D_ The company has four divisions:_x000D_

_x000D_
1. The Primary Care division markets products in the areas of pain management and gastroenterology. 
_x000D_
2. The Specialty Care-Methabolics and Urology division provides solutions in the areas of thyroid, obesity, diabetes and benign prostatic hyperplasia. 
_x000D_
3. The Specialty Care-Neuroscience division has a varied portfolio with specialty products in neurology and psychiatric segments.
_x000D_
4. Hospital Care offers products in the field of anesthesiology and neonatology, such as Forane, Sevorane and Survanta.
_x000D_

_x000D_

Subsidiaries

_x000D_ The company does not have any subsidiaries as of March 31, 2023._x000D_

Key Personnel

_x000D_ Mr. Munir Shaikh, Chairman_x000D_ _x000D_ Mr. Sheikh joined Abbott in 1968 and has served in several management positions with Abbott Asia, Latin America and the United States, including as General Manager in Pakistan, as Director of Business Development, Regional Director of Pacific / Asia / Africa, etc. _x000D_ _x000D_ Mr. Vivek V Kamath, Managing Director_x000D_ _x000D_ Mr. Kamath has over 30 years of rich and diversified experience in healthcare, including pharmaceuticals, OTC and diagnostics. Prior to joining the Company, Mr Kamath worked as the General Manager of the Specialty Care business of Abbott Healthcare Private Limited. Prior to Abbott, he worked with MSD Pharmaceuticals; Roche Diagnostics, India; Novartis, Singapore; Ranbaxy; Pfizer, India; Fulford, India; Wockhardt and Johnson & Johnson._x000D_

Corporate Actions

_x000D_ The company has not performed any rights issue, bonus issue, stock split or buyback in recent years._x000D_ _x000D_ Mergers and Acquisitions_x000D_

_x000D_
• In 2010, the company’s board of directors approved the draft scheme for the amalgamation of Solvay Pharma India into Abbott India.
_x000D_
• In the year 2003, the company's wholly-owned subsidiary company, Lenbrook Pharmaceuticals Ltd, was amalgamated with the company.
_x000D_

_x000D_

Financial Performance

_x000D_

_x000D_
• The company has increased its sales by 30.68% from ₹4,093 crore in FY 2020 to ₹5,349 crore in FY 2023.
_x000D_
• In the same period, its operating profit margin increased from 18% to 23%.
_x000D_
• In the aforementioned period, its positive cash flow has also increased from ₹8 crore to ₹107 crore.
_x000D_